The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile

MC Dalakas - Pharmacology & therapeutics, 2004 - Elsevier
Intravenous immunoglobulin (IVIg) has multiple actions on the immunoregulatory network
that operate in concert with each other. For each autoimmune neuromuscular disease …

Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies

MC Dalakas - Neurology, 2002 - AAN Enterprises
Intravenous immunoglobulin (IVIg) is an immunomodulating agent that has multiple
activities, including modulation of complement activation products, suppressing idiotypic …

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

MC Dalakas - Muscle & Nerve: Official Journal of the American …, 1999 - Wiley Online Library
This review summarizes the current status of intravenous immunoglobulin (IVIg) in the
treatment of autoimmune neuromuscular disorders and the possible mechanisms of action …

Impact of autoantibody glycosylation in autoimmune diseases

R Goulabchand, T Vincent, F Batteux, J Eliaou… - Autoimmunity …, 2014 - Elsevier
Objective: Recent outcomes enhanced the critical role of glycosylation pattern of
autoantibodies in the pathophysiology of antibody-mediated autoimmune diseases. In this …

Sialylation levels of anti–proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's)

C Espy, W Morelle, N Kavian, P Grange… - Arthritis & …, 2011 - Wiley Online Library
Objective To investigate whether the glycosylation and sialylation levels of anti–proteinase 3
(anti‐PR3) antibodies could affect their pathogenicity, and whether these levels could be …

Immunoglobulins inhibit pathophysiological effects of anti‐GQ1b‐positive sera at motor nerve terminals through inhibition of antibody binding

BC Jacobs, GM O'Hanlon, RWM Bullens, J Veitch… - Brain, 2003 - academic.oup.com
High‐dose intravenous immunoglobulin (IVIg) is an effective treatment for many antibody‐
mediated neuromuscular diseases, suggesting that IVIg directly interferes with the pathways …

Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy—a new mechanism of action?

S Bick, M Tschernatsch, A Karg, V Fuehlhuber… - Journal of …, 2013 - Elsevier
Chronic-inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated
disease treated with intravenous immunoglobulin (IVIg). The underlying mechanism of …

The effect of container surface passivation on aggregation of intravenous immunoglobulin induced by mechanical shock

S Movafaghi, H Wu, IM Francino Urdániz… - Biotechnology …, 2020 - Wiley Online Library
Aggregation of therapeutic proteins can result from a number of stress conditions
encountered during their manufacture, transportation, and storage. This work shows the …

Intravenous immunoglobulin attenuates airway hyperresponsiveness in a murine model of allergic asthma

GN Kaufman, AH Massoud… - Clinical & …, 2011 - Wiley Online Library
Background Intravenous immunoglobulin (IVIG) has potent anti‐inflammatory and immune‐
modulating properties. IVIG has been utilized as a steroid‐sparing agent in severe asthma …

Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis

SH Jorgensen, PS Sorensen - Journal of the neurological sciences, 2005 - Elsevier
Intravenous immunoglobulin (IVIG) is an established treatment of immune-mediated
demyelinating neuropathy. Since IVIG possesses multiple immunomodulatory and anti …